The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...

That said, the financial results of both Apple and Amazon had some weaknesses under the hood. Apple's Services division, ...

Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S. and petitioning ...

Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene ...

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...

The obesity pipeline was strengthened with Zealand's amylin drug petrelintide. Roche is also awaiting key readouts this year for giredestrant (breast cancer) and fenebrutinib (multiple sclerosis).

Roche is also expanding its presence in the cardiovascular, renal, and metabolism (CVRM) space, with Petrelintide emerging as a promising candidate for obesity treatment. Following the acquisition ...